Insulin degludec: No hint of added benefit in children and adolescents
Severe side effects more frequent in girls with type 1 diabetes; no data for type 2 diabetes
2015-06-01
(Press-News.org) Insulin degludec (trade name: Tresiba) has been approved since January 2015 for adolescents and children from the age of one year with type 1 or type 2 diabetes mellitus. In an early benefit assessment pursuant to the Act on the Reform of the Market for Medicinal Products (AMNOG), the German Institute for Quality and Efficiency in Health Care (IQWiG) has now examined whether this new drug, alone or in combination with other blood-glucose lowering drugs, offers an added benefit over the appropriate comparator therapy.
No added benefit of insulin degludec for adolescents and children with type 1 diabetes mellitus can be derived from the dossier. However, in girls there is a hint of greater harm regarding serious adverse events. Since the manufacturer presented no data for adolescents and children with type 2 diabetes, no conclusion on greater or lesser benefit can be drawn for this therapeutic indication.
Type 1 and type 2 diabetes mellitus are different diseases
In contrast to its dossier for the benefit assessment of insulin degludec in adults in summer 2014, the manufacturer did not differentiate between type 1 and type 2 diabetes in the analysis of study data in its current dossier. It justified this by claiming that the therapeutic indication was not differentiated in the Summary of Product Characteristics, which generally recommended intensive insulin therapy for adolescents and children.
IQWiG, in contrast, differentiated between type 1 and type 2 diabetes mellitus in the dossier assessment because these are two different diseases: In type 1 diabetes, there is an absolute insulin deficiency so that substitution of insulin is vital. In type 2 diabetes, there is a relative insulin deficiency, which can also be (partly) compensated by other interventions or drugs. This results in different treatment recommendations for the two diseases in the Summary of Product Characteristics, from which children and adolescents are not exempt.
No advantages for children and adolescents with type 1 diabetes
The only study presented by the manufacturer in its dossier investigated children and adolescents with type 1 diabetes. The results showed no differences between the treatment groups regarding mortality, symptoms and complaints, as well as most side effects (discontinuation due to side effects, severe and symptomatic hypoglycaemia, ketoacidosis). Health-related quality of life was not investigated. Hence no hint of an added benefit of insulin degludec could be derived for these outcomes.
More side effects in girls with type 1 diabetes
Neither positive nor negative effects were determined for boys. In girls with type 1 diabetes mellitus who were treated with insulin degludec, however, serious adverse events occurred more frequently than in the comparator group: Within 52 weeks, severe side effects occurred in approximately 15 of 100 girls who received insulin degludec. In girls who received standard treatment, this was the case in approximately 3 of 100 girls. Hence there is a hint of lesser benefit of insulin degludec versus the appropriate comparator therapy in the treatment of girls.
No data for type 2 diabetes mellitus
The manufacturer presented no data in its dossier for adolescents and children from the age of one year with type 2 diabetes mellitus. No hint of an added benefit of insulin degludec in comparison with the appropriate comparator therapy can therefore be derived.
INFORMATION:
G-BA decides on the extent of added benefit
This dossier assessment is part of the early benefit assessment according to the Act on the Reform of the Market for Medicinal Products (AMNOG) supervised by the Federal Joint Committee (G-BA). After publication of the dossier assessment, the G-BA conducts a commenting procedure and makes a final decision on the extent of the added benefit.
An overview of the results of IQWiG's benefit assessment is given by a German-language executive summary. In addition, the Website gesundheitsinformation.de, published by IQWiG, provides easily understandable German-language information.
More English-language information will be available soon (Sections I 2.1 to I 2.6 and Sections II 2.1 to II 2.6 of the dossier assessment as well as subsequently published health information on informedhealthonline.org). If you would like to be informed when these documents are available, please send an e-mail to » info@iqwig.de.
ELSE PRESS RELEASES FROM THIS DATE:
2015-06-01
The effort to identify new ways of fighting infections has taken a step forward now that scientists have identified a key protein involved in the host's response to strep infections. This protein, called "NFAT," appears to play a key role in the body's inflammatory response to an infection, which when uncontrolled, can be as bad, if not worse, than the infection itself. Furthermore, this discovery was made using streptococcal bacteria, which are responsible for a wide range of human illnesses, ranging from sore throat and pink eye to meningitis and bacterial pneumonia. ...
2015-06-01
CAMBRIDGE, Mass--Most of the world's electricity-producing power plants -- whether powered by coal, natural gas, or nuclear fission -- make electricity by generating steam that turns a turbine. That steam then is condensed back to water, and the cycle begins again.
But the condensers that collect the steam are quite inefficient, and improving them could make a big difference in overall power plant efficiency.
Now, a team of researchers at MIT has developed a way of coating these condenser surfaces with a layer of graphene, just one atom thick, and found that this can ...
2015-06-01
Chicago, IL, USA (30 May 2015) -- The benefits of adding liver-directed SIR-Spheres Y-90 resin microspheres to a current systemic chemotherapy for the first-line treatment of unresectable metastatic colorectal cancer (mCRC) reported in the SIRFLOX study, were presented at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. The results of the 530-patient SIRFLOX randomized controlled study, which open new possibilities for combining radiation targeted at liver metastases with first-line systemic treatment of mCRC, were presented by Associate Professor ...
2015-06-01
Chicago and Madrid, June 1st 2015: PharmaMar today announced data from a Phase 1b study of the transcriptional inhibitor PM1183 in combination with doxorubicin in second line therapy in patients with small cell lung cancer (SCLC) showing that the treatment induced objective responses in 67% of the patients, including 10% of them where all signs of cancer disappeared (complete responses). Every patient with SCLC denominated primary chemotherapy-sensitive (their chemotherapy-free interval (CTFI) is more than 90 days) responded to treatment, including 18% of complete responses. ...
2015-06-01
Chicago and Madrid, June 1st 2015: PharmaMar today announced data from a Phase 2 study in patients with sarcomatoid/biphasic malignant pleural mesothelioma showing that 41.2% (95% CI: 18.4-67.1) of patients treated with the anticancer drug trabectedin in second line were alive and free of progression at 12 weeks. The median progression-free survival (PFS) in these 17 evaluated patients was 8.3 weeks. There were 5 patients who continue receiving trabectedin beyond 12 weeks.
"Mesothelioma patients usually do not respond to second-line treatments so the preliminary data ...
2015-06-01
PORTLAND, Ore., June 01, 2015 -- Women who took vitamin D and calcium supplements had the same number of menopausal symptoms as women who did not take the supplements, according to a study published today in Maturitas, the official journal of the European Menopause and Andropause Society.
The study, which involved 34,157 women ages 50-79, is part of the Women's Health Initiative, one of the largest clinical trials ever undertaken to address the most common causes of death, disability and impaired quality of life in menopausal women.
"Our study suggests that women ...
2015-06-01
Aging is associated with significant decline in cognitive functions. But does this translate into poorer decision making? Psychologists from the University of Basel and the Max Planck Institute for Human Development report that in simple decision situations, older adults perform just as well as younger adults. However, according to their study published in the academic journal Cognition, aging may affect decision performance in more complex decision situations.
Important decisions in politics and economics are often made by older people: According to Forbes magazine, ...
2015-06-01
The NHS could achieve up to twice as much with the resources that the Government plans to spend introducing a full seven day service in the NHS in England, according to new research from The University of Manchester.
Health economists, working with colleagues at the University of York, have used official data to suggest an extra 5,353 deaths each year occur when people are admitted to hospital at the weekend rather than mid-week, but that the £1.43 billion cost of removing this risk would be better spent on other priorities.
Despite a seven day health service ...
2015-06-01
Researchers have developed a new augmented reality display that allows the audience to explore 3D augmentations of digital musical performances in order to improve their understanding of electronic musicians' engagement.
The diversity of digital musical instruments keeps increasing, especially with the emergence of software and hardware that musicians can modify. While this diversity creates novel artistic possibilities, it also makes it more difficult for the audience to appreciate what the musicians are doing during performances. Contrary to acoustic instruments, digital ...
2015-06-01
London, UK (1st June, 2015) - Factors influencing food intake have, and continue to be, a hotly contested subject. A new paper published today in the SAGE journal, Journal of Health Psychology (JHP), suggests that disrupted sleep could be one factor contributing to excessive food intake and thus leading to long term chronic health damage in both adults and children.
In a special issue on Food, Diets, and Dieting, the paper explores how a bad night's sleep - something that affects millions of people worldwide - can affect eating habits and behaviors. Though it is well-known ...
LAST 30 PRESS RELEASES:
[Press-News.org] Insulin degludec: No hint of added benefit in children and adolescents
Severe side effects more frequent in girls with type 1 diabetes; no data for type 2 diabetes
